United States (US)

PEDF recombinant protein

Cat No. GTX65195

Reactivity Human
Species Human

Calculated MW

44.5 kDa. ( Note )


Lyophilized powder


20 mM PBS & 150 mM NaCl pH-7.4.


Reconstitute in sterile ddH2O. Store at -20ºC.

Antigen Species


Expression System

E. coli


Purity was assessed by SDS-PAGE (≥95%) and by HPLC (≥95%).


For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.


Osteosarcoma-derived Growth Factor, Gliomaderived growth factor, PDGF-1, PDGF1, PDGFAA, PDGFA, Osteosarcomaderived Growth Factor, Glioma-derived growth factor, GDGF, ODGF, PDGF-AA, PDGF-A, PDGF 1, PDGF A, PDGF AA, Glioma derived growth factor


PEDF is a noninhibitory serpin with neurotrophic, anti-angiogenic, and anti-tumorigenic properties. PEDF is a 50,000 dalton glycoprotein created and secreted in many tissues all the way through the body. A key component of the anti-angiogenic action of PEDF is the induction of apoptosis in proliferating endothelial cells. Additionally, PEDF is capable to inhibit the activity of angiogenic factors such as VEGF and FGF-2. The recognition of a lipase-linked cell membrane receptor for PEDF (PEDF-R) that binds to PEDF with high affinity should facilitate further elucidation of the underlying mechanisms of this pluripotent serpin. The unique range of PEDF activities associate it as a potential therapeutic agent for the treatment of vasculature related neurodegenerative diseases such as age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR). PEDF in addition has the potential to be functional in the treatment of various angiogenesis-related diseases including a number of cancers. Recombinant human PEDF produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 400 amino acids and having a molecular mass of 44.5 kDa.

Research Area

Package List Price ($)
$ 259